1-O-Alkyl-2-acetyl-sn-glyceryl-3-phosphorylcholine (PAF) is a minor lipid component in Tetrahymena pyriformis cells  by Lekka, Marilena et al.
Volume 208, number 1 FEBS 4165 November 1986 
l-O-Alkyl-2-acetyl-sn-glyceryl-3-phosphorylcholine (PAF) 
is a minor lipid component in Tetrahymena pyrz$ormis cells 
Marilena Lekka, Alexandros D. Tselepis and Demokritos Tsoukatos* 
Luborutory of Biochemistry, Department of Chemistry, University qf loannina. Ioannina 45110, Greece 
Received 10 September 1986 
The protozoan Tetrahymena pyriformis contains 4.2 f 2.2 ng PAF/lO’ cells. Only I-32 of this lipid is re- 
leased in the cell free medium. PAF production is not influenced by different extracellular Ca*+ concentra- 
tions. Cell stimulation with calcium ionophore A23187 or zymosan particles does not affect the amount 
of PAF either. This is the first report of a natural occurrence of PAF in a protozoan. 
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1. INTRODUCTION 
Platelet-activating factor, the potent mediator in 
inflammatory and allergic reactions, is known to 
be released from a variety of tissues and cell types 
under stimulation [l-6]. Its presence in 
physiological fluids without immunologic 
challenge has also been reported although its 
cellular origin is not well documented [7-91. 
l-0-Alkyl-2-acyl-sn-glyceryl-3-phosphorylcho- 
line, the effective precursor of PAF [lo-121, is a 
major component of Tetrahymena pyriformis 
lipids. Therefore we investigated the possibility of 
PAF production by the protozoan under various 
incubation conditions or stimulation. 
2. EXPERIMENTAL 
2.1. Materials 
Buffer A, pH 7: 50 mM NaCI, 2.5 mM KCl, 
* To whom correspondence should be addressed 
Abbreviations: PAF, platelet-activating factor; PLA2, 
phospholipase AZ; BSA, bovine serum albumin; 
CPICPK, creatine phosphate/creatine phosphokinase 
1 mM MgClz.6Hz0, 5mM D( + )-glucose, 
0.1 mM KH2P04, 0.4 mM K2HP04 and 0.2 mM 
EGTA. Buffer B, pH 7.2: same as buffer A 
without EGTA but containing 1.7 mM CaCl2 and 
0.5 mM NaHCO3. Buffer C, pH 7.2: same as buf- 
fer B, containing 0.9 mM CaCl2. 
Aggregation buffers: tyrode-gelatine-EGTA 
(TG-EGTA) buffer solution, pH 6.5, was used for 
washing the rabbit platelets and tyrode-gelatine- 
Ca2+ (TG-Ca2+) buffer solution, pH 7.4, was used 
for aggregation buffer [2]. 
Platelet aggregation was measured on a Chrono- 
log Co. aggregometer [2]. 
2.2. Incubation procedures 
T. pyriformis strain W cells were harvested at 
the late log-phase by centrifugation, washed 3 
times with the buffer A, fractionated into 3 parts 
and suspended, under agitation at 22”C, in the 
buffer solutions A, B and C, respectively. Cell den- 
sity counted in a hemocytometer was found to be 
3 x lo6 cells/ml. 
The cells suspended in buffer B were stimulated 
with an ionophore A23 187 solution in DMSO 
(final concentration 5.2 PM) or with zymosan par- 
ticles (final concentration 1 mg/ml). 
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2.3. Lipid isolation and purification 
At indicated time intervals, the lipids of 2.5 ml 
cell suspension were extracted according to Bligh 
and Dyer [13]. The cell free supernatant was also 
extracted and examined for PAF activity. The lipid 
samples were subjected to preparative TLC using 
chloroform/methanol/water (65 : 35 : 6) as a sol- 
vent system. The region between the standard 
lipids sphingomyelin and lyso-phosphatidylcholine 
was scraped and the lipid residue was extracted 
[14]. After total elimination of the solvents, the 
lipid residue was dissolved in BSA/saline, 
2.5 mg/ml, and tested for biological activity on 
washed rabbit platelets. The biologically active 
lipid was further purified by HPLC using a 
Micropak Si-10 column, and [3H]PAF as a stan- 
dard [15]. 
2.4. PAF determination 
The biologically active phospholipid was iden- 
tified as PAF through its chromatographic 
behaviour on TLC and HPLC, its physicochemical 
properties with respect to Pinckard tests [16] and 
its behaviour under treatment with PLA2 and 
Fig. 1. (a) Purification of T. pyriformis derived PAF by 
silica HPLC using acetonitrile/methanol/75% 
phosphoric acid (130: 5 : 1.5). (b) Separation of 
phospholipid standards and 3H-labeled PAF by silica 
HPLC, with the same solvent system as above. 
lipase from Rhizopus arrhizus [17]. It was also 
characterized and quantitatively determined by its 
ability to aggregate aspirin-treated washed rabbit 
platelets, in the presence of CP/CPK [2]. The ag- 
gregation curves were compared to those of stan- 
dard solutions of beef-heart derived PAF. 
3. RESULTS 
T. pyriformis suspended in buffer B produced 
without any stimulation 4.2 + 2.2 ng/lO’ cells of 
a biologically active phospholipid. This production 
was time independent and only l-3% of this com- 
pound was determined in the cell free medium 
Table 1 
PAF determination in T. pyriformis cell suspension in 
buffer B as well as in the cell free medium, without 
stimulation 
Time (min) 1 10 30 60 
PAF (ng/lO’ 
cells) 4.2k2.2 3.8kl.8 5.6k2.5 4.1 k1.5 
PAF in the 
medium (t70) 2.1 1.5 2.8 1.3 
Values represent the mean f SD, n = 8 
Table 2 
PAF determination in T. pyriformis cell suspension in 
buffers A, B and C without stimulation and in buffer B 
after treatment with Ca’+ ionophore A23187 and 
zymosan particles 
Solutions Amount of PAF, 
ng/lO’ cells 




A23187 in buffer B, 5.2,~M 
Zymosan particles in buffer B, 
3.0 + 1.8 
4.1 ?I 1.5 
3.8 + 1.0 
3.7 + 1.2 
1 mg/ml 3.6 k 1.9 
Values represent the mean + SD, n = 8. PAF was also 
determined at time intervals of 1, 10 and 30 min in the 
above conditions. No significant value fluctuations were 
observed. DMSO was used as control for the PAF 
determination after treatment with ionophore A23 187. 
It did not affect the PAF content in the cells 
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(table 1). The phospholipid migrated on TLC at an 
Rf 0.35, and on HPLC it was eluted at 24 min, 
identically to [3H]PAF (fig.la,b). 
The aggregation activity on washed rabbit 
platelets was maintained after treatment with 
lipase, but it was completely lost after incubation 
with PLA2. The phospholipid exhibited the same 
physicochemical behaviour as beef-heart derived 
PAF with respect to the Pinckard tests [16]. 
No significant modification of the phospholipid 
content in the cells was observed after treatment 
with calcium ionophore A23187 or zymosan par- 
ticles. The absence as well as the presence of dif- 
ferent extracellular Ca2+ concentrations do not 
affect the phospholipid amount in the cell. The 
PAF value appears also to be time independent 
(table 2). 
4. DISCUSSION 
T. pyriformis contains a variety of biologically 
active compounds such as serotonin, porphyrins 
and catecholamines [18], compounds which occur 
and play an important role in higher organisms. 
The protozoan is considered to be a good model 
for studies of membrane behaviour and of the 
biochemistry of its unusual lipids [ 191. 
Our results show that the isolated biologically 
active phospholipid exhibits identical properties to 
beef-heart derived PAF. This is the first report 
which concludes that PAF is a natural minor com- 
ponent in the protozoan lipids. The fact that PAF 
biosynthesis is not influenced by Ca2+ ionophore 
A23 187 or different extracellular Ca2+ concentra- 
tions, strongly suggests that it is not affected by 
Ca2+-dependent PLA2. PAF production is not in- 
fluenced by zymosan particles either. 
The pathway for PAF formation in mammalian 
cells studied most, involves Ca2+-dependent PLA2 
and acetyltransferase. 1-O-Alkyl-2-acyl-sn-glyce- 
ryl-3-phosphorylcholine is used as substrate 
[20-241. Another pathway involving phosphocho- 
linetransferase and I-0-alkyl-2-acetyl-sn-glycerol 
as a substrate has been proposed. This pathway re- 
quires Mg2+ and is inhibited by Ca2+ [25,26]. 
Our results do not clearly demonstrate the way 
of PAF formation in T. pyriformis. Nevertheless 
this protozoan could be proposed as a model for in 
vivo studies of PAF metabolism and its 
physiological role in the cell. 
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